BIOLINERX IN-LICENSES BL-3010 FROM GEVYS PHARMACEUTICALS

BioLineRx, Ltd., Israel's leading drug development company, today announced that it has signed an exclusive worldwide licensing agreement with Gevys Pharmaceuticals Ltd. for the development and commercialization of BL-3010, a novel approach for the treatment of acute and chronic pain. Gevys's patented technology utilizes a combination of approved drugs to dramatically increase the potency of micro-doses of classical pain medications.

Genetic Engineering News (http://www.genengnews.com/news/bnitem.aspx?name=1910754)